Page 1329 - Williams Hematology ( PDFDrive )

1304 Part X: Malignant Myeloid Diseases Chapter 84: Polycythemia Vera 1305

149. Shih LY, Lee CT, See LC, et al: In vitro culture growth of erythroid progenitors and 179. Barosi G, Mesa R, Finazzi G, et al: Revised response criteria for polycythemia vera
serum erythropoietin assay in the differential diagnosis of polycythaemia. Eur J Clin and essential thrombocythemia: An ELN and IWG-MRT consensus project. Blood
Invest 28(7):569–576, 1998. 121(23):4778–4781, 2013.
150. Fisher MJ, Prchal JF, Prchal JT, et al: Anti-erythropoietin (EPO) receptor monoclonal 180. Harrison C: Rethinking disease definitions and therapeutic strategies in essential
antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in thrombocythemia and polycythemia vera. Hematology Am Soc Hematol Educ Program
polycythemia vera. Blood 84(6):1982–1991, 1994. 2010:129–134, 2010.
151. Kralovics R, Sokol L, Prchal JT: Absence of polycythemia in a child with a unique 181. Tefferi A: Polycythemia vera and essential thrombocythemia: 2013 Update on diagno-
erythropoietin receptor mutation in a family with autosomal dominant primary poly- sis, risk-stratification, and management. Am J Hematol 88(6):507–516, 2013.
cythemia. J Clin Invest 102(1):124–129, 1998. 182. Dingli D, Tefferi A: Hydroxyurea: The drug of choice for polycythemia vera and essen-
152. Acharya J, Westwood NB, Sawyer BM, et al: Identification of latent myeloproliferative tial thrombocythemia. Curr Hematol Malig Rep 1(2):69–74, 2006.
disease in patients with Budd-Chiari syndrome using X-chromosome inactivation pat- 183. Barbui T, Finazzi G: Evidence-based management of polycythemia vera. Best Pract Res
terns and in vitro erythroid colony formation. Eur J Haematol 55(5):315–321, 1995. Clin Haematol 19(3):483–493, 2006.
153. Pagliuca A, Mufti GJ, Janossa-Tahernia M, et al: In vitro colony culture and chromo- 184. Antonioli E, Carobbio A, Pieri L, et al: Hydroxyurea does not appreciably reduce JAK2
somal studies in hepatic and portal vein thrombosis—Possible evidence of an occult V617F allele burden in patients with polycythemia vera or essential thrombocythemia.
myeloproliferative state. Q J Med 76(281):981–989, 1990. Haematologica 95(8):1435–1438, 2010.
154. Tefferi A, Thiele J, Vardiman JW: The 2008 World Health Organization classification 185. Ricksten A, Palmqvist L, Johansson P, et al: Rapid decline of JAK2V617F levels during
system for myeloproliferative neoplasms: Order out of chaos. Cancer 115(17):3842– hydroxyurea treatment in patients with polycythemia vera and essential thrombocythe-
3847, 2009. mia. Haematologica 93(8):1260–1261, 2008.
155. Lakey MA, Pardanani A, Hoyer JD, et al: Bone marrow morphologic features in poly- 186. Spanoudakis E, Bazdiara I, Kotsianidis I, et al: Hydroxyurea (HU) is effective in reduc-
cythemia vera with JAK2 exon 12 mutations. Am J Clin Pathol 133(6):942–948, 2010. ing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythe-
156. Wang X, LeBlanc A, Gruenstein S, et al: Clonal analyses define the relationships mia (ET) and polycythemia vera (PV) patients. Ann Hematol 88(7):629–632, 2009.
between chromosomal abnormalities and JAK2V617F in patients with Ph-negative 187. Zalcberg IR, Ayres-Silva J, de Azevedo AM, et al: Hydroxyurea dose impacts hemato-
myeloproliferative neoplasms. Exp Hematol 37(10):1194–1200, 2009. logic parameters in polycythemia vera and essential thrombocythemia but does not
157. Beutler E, Yeh M, Fairbanks VF: The normal human female as a mosaic of X-chromo- appreciably affect JAK2-V617F allele burden. Haematologica 96(3):e18–e20, 2011.
some activity: Studies using the gene for C-6-PD-deficiency as a marker. Proc Natl Acad 188. Sirhan S, Lasho TL, Hanson CA, et al: The presence of JAK2V617F in primary mye-
Sci U S A 48:9–16, 1962. lofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to
158. Prchal JT: Pathogenetic mechanisms of polycythemia vera and congenital polycythemic hydroxyurea. Am J Hematol 83(5):363–365, 2008.
disorders. Semin Hematol 38(1 Suppl 2):10–20, 2001. 189. Lanzkron S, Strouse JJ, Wilson R, et al: Systematic review: Hydroxyurea for the treat-
159. Swierczek SI, Piterkova L, Jelinek J, et al: Methylation of AR locus does not always ment of adults with sickle cell disease. Ann Intern Med 148(12):939–955, 2008.
reflect X chromosome inactivation state. Blood 119(13):e100–e109, 2012. 190. Tefferi A, Rumi E, Finazzi G, et al: Survival and prognosis among 1545 patients with
160. Swierczek SI, Agarwal N, Nussenzveig RH, et al: Hematopoiesis is not clonal in healthy contemporary polycythemia vera: An international study. Leukemia 27(9):1874–1881,
elderly women. Blood 112(8):3186–3193, 2008. 2013.
161. Vogelstein B, Fearon ER, Hamilton SR, et al: Use of restriction fragment length poly- 191. Alvarez-Larran A, Pereira A, Cervantes F, et al: Assessment and prognostic value of
morphisms to determine the clonal origin of human tumors. Science 227(4687):642– the European LeukemiaNet criteria for clinicohematologic response, resistance, and
645, 1985. intolerance to hydroxyurea in polycythemia vera. Blood 119(6):1363–1369, 2012.
162. Allen RC, Zoghbi HY, Moseley AB, et al: Methylation of HpaII and HhaI sites near 192. Barosi G, Birgegard G, Finazzi G, et al: A unified definition of clinical resistance
the polymorphic CAG repeat in the human androgen-receptor gene correlates with X and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofi-
chromosome inactivation. Am J Hum Genet 51(6):1229–1239, 1992. brosis: Results of a European LeukemiaNet (ELN) consensus process. Br J Haematol
163. Curnutte JT, Hopkins PJ, Kuhl W, et al: Studying X inactivation. Lancet 339(8795):749, 148(6):961–963, 2010.
1992. 193. Sever M, Newberry KJ, Verstovsek S: Therapeutic options for patients with polycythe-
164. Prchal JT, Guan YL, Prchal JF, et al: Transcriptional analysis of the active X-chromo- mia vera and essential thrombocythemia refractory/resistant to hydroxyurea. Leuk
some in normal and clonal hematopoiesis. Blood 81(1):269–271, 1993. Lymphoma 55(12):2685–2690, 2014.
165. McMullin MF, Reilly JT, Campbell P, et al: Amendment to the guideline for diagno- 194. Treatment of polycythaemia vera by radiophosphorus or busulphan: A randomized
sis and investigation of polycythaemia/erythrocytosis. Br J Haematol 138(6):821–822, trial. “Leukemia and Hematosarcoma” Cooperative Group, European Organization for
2007. Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer 44(1):75–80, 1981.
166. Bench AJ, White HE, Foroni L, et al: Molecular diagnosis of the myeloproliferative neo- 195. Kuriakose ET, Gjoni S, Wang YL, et al: JAK2V617F allele burden is reduced by busulfan
plasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. therapy: A new observation using an old drug. Haematologica 98(11):e135–e137, 2013.
Br J Haematol 160(1):25–34, 2013. 196. Alvarez-Larrán A, Martínez-Avilés L, Hernández-Boluda JC, et al: Busulfan in patients
167. Samuelson SJ, Parker CJ, Prchal JT: Revised criteria for the myeloproliferative disorders: with polycythemia vera or essential thrombocythemia refractory or intolerant to
Too much too soon? Blood 111(3):1741; author reply 1742, 2008. hydroxyurea. Ann Hematol 93(12):2037–2043, 2014.
168. Barbui T, Thiele J, Vannucchi AM, et al: Rethinking the diagnostic criteria of polycythe- 197. Tefferi A: Polycythemia vera: A comprehensive review and clinical recommendations.
mia vera. Leukemia 28(6):1191–1195, 2014. Mayo Clin Proc 78(2):174–194, 2003.
169. Silver RT, Chow W, Orazi A, et al: Evaluation of WHO criteria for diagnosis of poly- 198. Balan KK, Critchley M: Outcome of 259 patients with primary proliferative poly-
cythemia vera: A prospective analysis. Blood 122(11):1881–1886, 2013. cythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional
170. Teofili L, Giona F, Martini M, et al: The revised WHO diagnostic criteria for Ph- nuclear medicine department with phosphorus-32—A 15 year review. Br J Radiol
negative myeloproliferative diseases are not appropriate for the diagnostic screen- 70(839):1169–1173, 1997.
ing of childhood polycythemia vera and essential thrombocythemia. Blood 110(9): 199. Roberts BE, Smith AH: Use of radioactive phosphorus in haematology. Blood Rev
3384–3386, 2007. 11(3):146–153, 1997.
171. Finazzi G, Barbui T: Evidence and expertise in the management of polycythemia vera 200. Silver RT: Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet
and essential thrombocythemia. Leukemia 22(8):1494–1502, 2008. 2(8607):403, 1988.
172. Barbui T, Carobbio A, Rambaldi A, et al: Perspectives on thrombosis in essential 201. Hasselbalch HC: A new era for IFN-alpha in the treatment of Philadelphia-negative
thrombocythemia and polycythemia vera: Is leukocytosis a causative factor? Blood chronic myeloproliferative neoplasms. Expert Rev Hematol 4(6):637–655, 2011.
114(4):759–763, 2009. 202. Hasselbalch HC, Larsen TS, Riley CH, et al: Interferon-alpha in the treatment of Phil-
173. Caramazza D, Caracciolo C, Barone R, et al: Correlation between leukocytosis and adelphia-negative chronic myeloproliferative neoplasms. Status and perspectives. Curr
thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. Ann Drug Targets 12(3):392–419, 2011.
Hematol 88(10):967–971, 2009. 203. Silver RT, Kiladjian JJ, Hasselbalch HC: Interferon and the treatment of polycythemia
174. Landolfi R, Di Gennaro L, Barbui T, et al: Leukocytosis as a major thrombotic risk vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 6(1):49–58,
factor in patients with polycythemia vera. Blood 109(6):2446–2452, 2007. 2013.
175. Gangat N, Strand J, Li CY, et al: Leucocytosis in polycythaemia vera predicts both infe- 204. Kiladjian JJ, Mesa RA, Hoffman R: The renaissance of interferon therapy for the treat-
rior survival and leukaemic transformation. Br J Haematol 138(3):354–358, 2007. ment of myeloid malignancies. Blood 117(18):4706–4715, 2011.
176. De Stefano V, Za T, Rossi E, et al: Leukocytosis is a risk factor for recurrent arterial 205. Jones AV, Silver RT, Waghorn K, et al: Minimal molecular response in polycythemia
thrombosis in young patients with polycythemia vera and essential thrombocythemia. vera patients treated with imatinib or interferon alpha. Blood 107(8):3339–3341, 2006.
Am J Hematol 85(2):97–100, 2010. 206. Larsen TS, Moller MB, de Stricker K, et al: Minimal residual disease and normalization
177. Vannucchi AM, Antonioli E, Guglielmelli P, et al: Clinical correlates of JAK2V617F of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia
presence or allele burden in myeloproliferative neoplasms: A critical reappraisal. Leu- vera. A report on molecular response patterns in seven patients in sustained complete
kemia 22(7):1299–1307, 2008. hematological remission. Hematology 14(6):331–334, 2009.
178. Barbui T, Barosi G, Birgegard G, et al: Philadelphia-negative classical myeloproliferative 207. Zhang ZR, Duan YC: Interferon apha 2b for treating patients with JAK2V617F positive
neoplasms: Critical concepts and management recommendations from European Leu- polycythemia vera and essential thrombocytosis. Asian Pac J Cancer Prev 15(4):1681–
kemiaNet. J Clin Oncol 29(6):761–770, 2011. 1684, 2014.

Kaushansky_chapter 84_p1291-1306.indd 1304 9/21/15 11:11 AM